Based on the HYLORIS PHARMA. S.A. stock forecast from 0 analysts, the average analyst target price for HYLORIS PHARMA. S.A. is not available over the next 12 months. HYLORIS PHARMA. S.A.’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of HYLORIS PHARMA. S.A. is Bearish, which is based on 1 positive signals and 4 negative signals. At the last closing, HYLORIS PHARMA. S.A.’s stock price was EUR 5.72. HYLORIS PHARMA. S.A.’s stock price has changed by +13.04% over the past week, +25.16% over the past month and -51.32% over the last year.
No recent analyst target price found for HYLORIS PHARMA. S.A.
No recent average analyst rating found for HYLORIS PHARMA. S.A.
Company Overview HYLORIS PHARMA. S.A.
Hyloris Pharmaceuticals SA engages in the research, development, and manufacture of pharmaceutical products to address unmet medical needs. The company offers Maxigesic IV, a combination of paracetamol and ibuprofen sodium dihydrate used for post-operative pain; Podofilox Gel, an antimycotic drug for the treatment of external genital and perianal warts caused by various types of the human papilloma virus; and Sotalol IV to treat atrial fibrillation. It also develops Aspirin IV and HY-074 IV to reduce the risk of morbidity and mortality associated with an emergency cardiac event, such as myocardial infarction or stroke; Milrinone ER for right heart failure due to left ventricular device; Dofetilide IV to treat atrial fibrillation; Metolazone IV for the treatment of salt and water retention, including edema accompanying congestive heart failure and renal diseases; and HY-075 IV to prevent and treat cardiovascular diseases. In addition, the company offers other value-added products comprising Tranexamic Acid Oral Rinse for preventing and treating excessive bleeding in patients on blood thinners undergoing dental procedures; Alenura to treat pain associated with interstitial cystitis/bladder pain syndrome; Miconazole/Domiphen Bromide cream for recurrent vulvovaginal candidiasis; PTX-252 to treat acute myeloid leukemia; Atomoxetine oral Liquid for the treatment of attention deficit hyperactivity disorder; HY-083 to treat idiopathic rhinitis; HY-088 for hypophosphatemia; HY-090 to treat burning mouth syndrome; and HY-091 for vulvar lichen sclerosis. The company was incorporated in 2012 and is headquartered in Liège, Belgium. Read Less
Hyloris Pharmaceuticals SA engages in the research, development, and manufacture of pharmaceutical products to address unmet medical needs. The company offers Maxigesic IV, a combination of paracetamol and ibuprofen sodium dihydrate used for post-operative pain; Podofilox Gel, an...Read More
Frequently Asked Questions About HYLORIS PHARMA. S.A. (52U:F) Stock
Stock Target Advisor's fundamental analysis for HYLORIS PHARMA. S.A.'s stock is Bearish.
Unfortunately we do not have enough data on 52U:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 52U:F's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on 52U:F's stock to indicate if its overvalued.
The last closing price of 52U:F's stock was EUR 5.72.
The most recent market capitalization for 52U:F is EUR 0.16B.
Unfortunately we do not have enough analyst data on 52U:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains HYLORIS PHARMA. S.A.'s stock.
As per our most recent records HYLORIS PHARMA. S.A. has 41 Employees.
HYLORIS PHARMA. S.A.'s registered address is Boulevard Patience et Beaujonc N°3/1, Liège, Belgium, 4000.
You can get more information about it from HYLORIS PHARMA. S.A.'s website at https://hyloris.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About HYLORIS PHARMA. S.A. (52U:F) Stock
Stock Target Advisor's fundamental analysis for HYLORIS PHARMA. S.A.'s stock is Bearish.
Unfortunately we do not have enough data on 52U:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 52U:F's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on 52U:F's stock to indicate if its overvalued.
The last closing price of 52U:F's stock was EUR 5.72.
The most recent market capitalization for 52U:F is EUR 0.16B.
Unfortunately we do not have enough analyst data on 52U:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains HYLORIS PHARMA. S.A.'s stock.
As per our most recent records HYLORIS PHARMA. S.A. has 41 Employees.
HYLORIS PHARMA. S.A.'s registered address is Boulevard Patience et Beaujonc N°3/1, Liège, Belgium, 4000.
You can get more information about it from HYLORIS PHARMA. S.A.'s website at https://hyloris.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for 52U:F !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
